47 results
424B5
ALTS
ALT5 Sigma Corp
23 Aug 24
Prospectus supplement for primary offering
2:44pm
Authorizations:
the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee
424B5
ALTS
ALT5 Sigma Corp
21 Jun 24
Prospectus supplement for primary offering
5:20pm
”). There are two types of Marketing Authorizations:
the Community MA, which is issued by the European Commission through the Centralized Procedure, based
424B5
ALTS
ALT5 Sigma Corp
6 May 24
Prospectus supplement for primary offering
4:57pm
(an “MA”). There are two types of Marketing Authorizations:
the Community MA, which is issued by the European Commission through the Centralized
424B5
wu4 ygbgm9h5wtemihwh
22 Aug 23
Prospectus supplement for primary offering
12:54pm
8-K
EX-99.1
ud4ue
22 Jul 21
JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients
9:46am
8-K
EX-99.1
yf9mtzdpuu 9hhoa
23 Jun 21
Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA
10:14am
8-K
EX-99.1
8493kpt5c
2 Feb 21
JanOne Announces Closing of $6.0 Million Common Stock Offering
5:27pm
424B5
8fyuz 7jthn6557sqbk
2 Feb 21
Prospectus supplement for primary offering
1:30pm
8-K
EX-99.1
4xs3k
21 Sep 20
Regulation FD Disclosure
9:15am
8-K
EX-99.1
2h1gkzdb1
26 Aug 20
JanOne Inc. (JAN) CEO Tony Isaac on Drug Candidate JAN101 - Telebriefing and Corporate Update Call Transcript
6:01am
8-K
EX-10.1
pj44j23ip
7 Feb 20
JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development
12:00am